Status:

COMPLETED

Intra Articular Injection of Microfat and PRP in Knee Osteoarthritis

Lead Sponsor:

Clinique Juge

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

The hypothesis of this project is that the injection of an innovative treatment (microfat and dose of autologous PRP) allows to delay knee arthroplasty in patients with knee OA resistant to medical tr...

Detailed Description

Osteoarthritis is the most common joint disease in the world and one of the most common causes of pain and functional disability. The incidence of cartilage pathology has grown due to the ageing popul...

Eligibility Criteria

Inclusion

  • Males and females between 20 to 65 years of age
  • Symptomatic knee osteoarthritis , ICRS grade 2, 3 ou 4 with VAS \> 4 and failure of medical treatment for at least one year
  • BMI between 20 to 30
  • Written informed consent, signed by patient or legal representative
  • HB \> 10g/dl
  • Negative pregnancy test
  • Social security affiliated

Exclusion

  • IRM contre-indications: ocular loose bodies, pace maker, neurostimulateur, cochlear implant, vascular clips, mettalic cardiac valve
  • BMI \< 20
  • Thrombocytopenia \< 150 G/L
  • Thrombocytosis \> 450 G/L
  • Thrombopathy
  • TP \< 70%
  • TCA patient / witness rapport \> 1,20
  • Anaemia: HB \< 10g/dl
  • Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA
  • Treatment by platelet inhibiting agent, aspirin, anti vitamin K completed more than 2 weeks before inclusion
  • Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion
  • Intra articular knee injection of corticosteroid more than 8 weeks before inclusion
  • Intra articular knee injection of hyaluronic acid more than 8 weeks before inclusion
  • NSAI treatment completed more than 2 weeks before inclusion
  • Fever or recent disease
  • Auto immune disease
  • Inflammatory Arthritis
  • Immune deficit
  • Infectious disease
  • Malignant tumor being treated or history of malignant tumor

Key Trial Info

Start Date :

November 15 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04352075

Start Date

November 15 2018

End Date

March 1 2020

Last Update

April 20 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Louis

Marseille, France, 13008